Discover essential information about Nivolumab, an innovative immunotherapy used in cancer treatments. Learn about its applications, efficacy based on clinical trials, how it works to boost immune response, and safety considerations. This overview provides a comprehensive understanding of this promising medication for oncological care.

Nivolumab, marketed as Opdivo, is an innovative cancer therapy recognized for its targeted immunological approach. Its approval was based on clinical trials showing significant benefits for patients battling various cancers. This medication is commonly prescribed for blood cancers and advanced non-small cell lung cancer, especially in cases of recurrence or metastasis after stem cell transplants and prior treatments like Adcetris.

What is Nivolumab?
It is a prescription immunotherapy recommended for specific cancer types, providing hope for patients with limited options.

Its safety and effectiveness in children with cancer are still being studied.

How Well Does Nivolumab Work?
Clinical studies reveal that Nivolumab can significantly reduce tumor size or eradicate tumors entirely in some patients. In one trial involving 95 patients with classical Hodgkin lymphoma, about 65% responded positively, with some experiencing complete remission.

How It Works
Acting as an immunotherapeutic agent, Nivolumab enhances T cell activity, enabling the immune system to better detect and attack cancer cells. It works by blocking the mechanisms cancer cells use to hide from immune detection.

As with all medications, side effects are possible and vary among individuals. It's essential to consult healthcare professionals before starting Nivolumab therapy.